Metabolic Health Program Combining GLP-1 Medication with Behavior Change Publishes Annual Results Demonstrating 15% Average Weight Loss at 12, 18, & 24 Months and Reversal of Diabetes or Prediabetes Diagnosis in 81% of Participants
Calibrate, the leading metabolic health company, released its second annual Results Report , demonstrating continued effectiveness of the Company’s comprehensive care model to treat overweight and obesity, including a 15% average sustained weight loss at 12, 18, and 24 months.
- Calibrate, the leading metabolic health company, released its second annual Results Report , demonstrating continued effectiveness of the Company’s comprehensive care model to treat overweight and obesity, including a 15% average sustained weight loss at 12, 18, and 24 months.
- The clinically-reviewed data demonstrates overall metabolic health improvements, and notably, the reversal of diabetes and prediabetes diagnoses in 81% of members.
- “Our most recent Results Report validates our initial vision: that a comprehensive program combining medication with behavior change is the standard of care for obesity treatment.
- “This is remarkable because it shows more sustained weight loss than the STEP 5 trials using Wegovy––while using a variety of different GLP-1 medications.